Devazepide

Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders[1].

Product Specifications

CAS Number

[103420-77-5]

Product Name Alternative

L-364,718; MK-329

UNSPSC

12352005

Hazard Statement

H300

Target

Cholecystokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/devazepide.html

Purity

99.55

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C(C1=CC2=C(C=CC=C2)N1)N[C@H]3N=C(C4=CC=CC=C4)C5=CC=CC=C5N(C)C3=O

Molecular Formula

C25H20N4O2

Molecular Weight

408.45

Precautions

H300

References & Citations

[1]Chang RS, et al. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci U S A. 1986 Jul;83 (13) :4923-6.|[2]Helen H Wang, et al. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice. Eur J Clin Invest|[3]E Vasar, et al. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Psychopharmacology (Berl) . 1991;105 (3) :393-9